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Abstract
Background: Growing evidence raises concern about possible associations of high selenium exposure with
diabetes in selenium-replete populations such as the US. In countries with lower selenium status, such as Italy,
there is little epidemiological evidence on the association between selenium and diabetes. This study examined
the prospective association between dietary selenium intake and risk of type 2 diabetes.
Methods: The ORDET cohort study comprised a large sample of women from Northern Italy (n = 7,182). Incident
type 2 diabetes was defined as a self-report of a physician diagnosis, use of antidiabetic medication, or a
hospitalization discharge. Dietary selenium intake was measured by a semi-quantitative food-frequency
questionnaire at the baseline examination (1987-1992). Participants were divided in quintiles based on their
baseline dietary selenium intake.
Results: Average selenium intake at baseline was 55.7 μg/day. After a median follow-up of 16 years, 253 women
developed diabetes. In multivariate logistic regression analyses, the odds ratio for diabetes comparing the highest
to the lowest quintile of selenium intake was 2.39, (95% CI: 1.32, 4.32; P for linear trend = 0.005). The odds ratio for
diabetes associated with a 10 μg/d increase in selenium intake was 1.29 (95% CI: 1.10, 1.52).
Conclusions: In this population, increased dietary selenium intake was associated with an increased risk of type 2
diabetes. These findings raise additional concerns about the association of selenium intake above the
Recommended Dietary Allowance (55 μg/day) with diabetes risk.
Background
Selenium is a key component of a number of selenopro-
teins involved in essential enzymatic functions, such as
redox homeostasis, thyroid hormone metabolism, immu-
nity and reproduction [1]. Because of antioxidant proper-
ties of selenoproteins, and because selenate mimics
insulin activity in experimental models [2,3], selenium
was expected to prevent type 2 diabetes and cardiovascu-
lar disease (CVD) [4]. However, recent findings from
observational studies and randomised clinical trials have
raised concerns with respect to possible adverse cardio-
metabolic effects of high selenium exposure, at least in
well-nourished populations. Specifically, several unrelated
studies from the US indicate that high selenium status or
selenium supplementation is associated with an increased
diabetes risk [5-8]. Furthermore, recent evidence from
several populations indicates that high selenium exposure
may also be associated with an adverse lipid profile [9-12]
and hypertension [13], raising additional concerns about
metabolic toxicity of high selenium exposure and pro-
longed use of selenium supplements [14].
Dietary intake of selenium varies considerably between
countries and regions largely due to the variability of
the selenium content of soil and hence of plant foods
and animal forage [15]. Current recommendations on
selenium intake are based on optimizing the activity of
plasma glutathione peroxidases, which are maximized at
intakes as high as 55 μg / d a y[ 1 6 ] .I nt h eU S ,s e l e n i u m
intake ranges from 60-220 μg/day [8,12,13,15] and it is
unclear if there are health benefits of increased selenium
intake above the Recommended Dietary Allowance
(RDA), or if metabolic toxicity might occur at these
levels. Selenium intakes in Europe are lower than in the
US, but with large between-country variability ranging
* Correspondence: S.Stranges@warwick.ac.uk
1Health Sciences Research Institute, University of Warwick Medical School,
Coventry, UK
Full list of author information is available at the end of the article
Stranges et al. BMC Public Health 2010, 10:564
http://www.biomedcentral.com/1471-2458/10/564
© 2010 Stranges et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.from adequate or marginally adequate (Western and
Central Europe: 30-90 μg/day) to low or deficient intake
(Eastern European countries: 7-30 μg/day) [15].
There is little epidemiological evidence on the associa-
tion of selenium with diabetes among European popula-
tions [17,18]. The objective of the present study was
thus to examine the association of dietary selenium
intake with risk of incident type 2 diabetes in the
ORDET cohort study, a large sample of women from
Northern Italy [19].
Methods
Study population
The ORDET study (HORmones and Diet in the ETiol-
ogy of Breast Cancer) is an ongoing prospective follow-
up study of 10,786 women residents of Varese province
in Northern Italy [19]. Between June 1987 and June
1992, healthy women 34 to 70 years of age were asked
to join the study by coming to the recruitment center.
Participants were recruited at public meetings, through
radio, television and newspaper advertising, and at
breast cancer prevention/early diagnosis units. Women
with a history of cancer, bilateral ovariectomy, or liver
disease, and women receiving hormone therapy in the
three months prior to recruitment to the study were not
eligible for the study. We excluded women who did not
fill in the lifestyle questionnaire (N = 96), who reported
t h ep r e s e n c eo ft y p e2d i a b e t e sa tt h eb a s e l i n ea s s e s s -
ment (N = 203), who did not compile the food fre-
quency questionnaire because it was not available at the
beginning of the study (N = 1,552), or who had missing
data in anthropometric variables (N = 54). We further
excluded participants in whom the ratio of total energy
intake (determined from the food frequency question-
naire) to basal metabolic rate was at either extreme of
the distribution (cut-offs 0.5 and 99.5 percentiles)
(N = 73), to reduce the impact of implausible extreme
values [20], as well as women who died during follow-
up from causes other than type 2 diabetes (N = 336).
Finally, 1,290 women could not be re-contacted over the
follow-up and were further excluded. After all these
exclusions, the final cohort comprised 7,182 partici-
pants. All participants signed an informed consent form.
The Ethical Review Board of the Italian National Cancer
Institute of Milan approved the study.
Baseline measurements
Diet was assessed using a semi-quantitative food-fre-
quency questionnaire designed to capture local dietary
habits [19]. Frequency of consumption and average daily
consumption of food and beverage items over the pre-
vious year were estimated using a 107-item question-
naire. To estimate daily consumption of macronutrients
and daily energy intake, these items were linked to the
Italian Food Tables for epidemiological studies [21].
We used two sources of data to estimate the selenium
content of the food items included in the ORDET food
frequency questionnaire. For several food items, we used
the nutritional database maintained by the Italian
National Institute of Nutrition, which in its 1997 edition
reported the average selenium content of several food-
stuffs distributed in Italy [22]. Since the selenium compo-
sition of some items in the ORDET questionnaire
(particularly for cereals and meats) could not be retrieved
in this database nor were they available from other
national sources, we carried out a specific measurement
by selecting samples of these foods distributed in North-
ern Italy from 1996 through 1998 and determining their
average selenium content by hydride-generation atomic
absorption spectrometry [23].
A lifestyle questionnaire was also completed by each
participant to collect detailed information on reproductive
history, alcohol consumption, smoking habits, medical
history, occupation, education and other socioeconomic
variables. Weight and height were measured at enrolment
by trained nurses according to a standardized protocol.
Body mass index (BMI) was calculated as weight divided
by height squared (kg/m
2).
Case ascertainment and verification
Follow-up information was collected through a tele-
phone interview in 2006-2007. The follow-up question-
naire included update information on weight,
menopausal status, incident disease and other factors.
Follow-up was available for approximately 79.1% of the
baseline cohort (mean follow-up: 16 years). The tele-
phone follow-up interviews asked whether participants
had received a diagnosis of type 2 diabetes from a physi-
cian after the baseline examination or if they were
taking medications for treatment of diabetes. In addition
to the follow-up questionnaire, information on hospitali-
zations and medication use during follow-up was
obtained by linking regional hospital discharge data-
bases, and prescription drug databases to the ORDET
database mainly via social security numbers.
In the present study, incident type 2 diabetes was
defined by the presence of at least three of the following
conditions: 1) a self-report of a physician diagnosis in
the follow-up questionnaire; 2) a self-report of use of
insulin or oral hypoglycemic medication in the follow-
up questionnaire; 3) evidence of a prescription for insu-
lin or oral hypoglycemic medication by linkage with
regional prescription drug database; or 4) a hospital dis-
charge record with the diagnosis of diabetes by linkage
with medical discharge records. These criteria complied
with the protocol of the InterAct Study, an EU-funded
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tries and 500,000 subjects with over 10,000 incident
diabetic cases http://www.inter-act.eu/.
Statistical analysis
The study population was categorized in quintiles of
energy-adjusted selenium intake at baseline using the
residual method [20]. Odds ratios (OR) for developing
type 2 diabetes comparing the highest to the lowest
quintile of selenium intake were estimated by logistic
regression analysis. We used two levels of adjustment:
model 1 (reduced model) was adjusted for age, educa-
tion and menopausal status; model 2 (fully-adjusted
model) was further adjusted for BMI (as a linear term),
smoking (never, past, current), alcohol intake (abstai-
ners, ≤ 12 g/day, > 12 g/day), energy intake (not from
alcohol), saturated/polyunsaturated fat ratio, animal pro-
teins, total carbohydrates, and body weight change
(delta-weight) between the baseline and follow-up exam-
inations. Tests for trend across selenium intake quintiles
were derived from likelihood ratio tests comparing mod-
els with and without a variable including the median
selenium intake at each quintile as a continuous vari-
able. We tested the interaction of selenium intake with
BMI categories (BMI ≤ 25 & > 25) and with menopausal
status using a likelihood rat i ot e s tt h a tc o m p a r e dt h e
model that included the product term and the model
that did not include it. We used STATA software
(version 10.0; Stata Corp., TX) for statistical analysis.
Results
Average selenium intake at baseline was 55.7 μg/day.
After a median follow-up of 16 years, 253 women devel-
oped type 2 diabetes. At baseline, women who devel-
oped diabetes over follow-up were on average older,
heavier, less educated, had higher dietary intakes of total
and animal proteins, consumed less alcohol, and were
more likely to be postmenopausal than women who did
not develop diabetes. In addition, they had a higher
mean dietary intake of selenium (60.9 vs. 56.8 μg/d,
P < 0.001) (Table 1).
Red meat and fish were the two main sources of diet-
ary selenium intake in this population (Table 2). Sele-
nium intake was positively associated with BMI, with
total and animal protein intake, and with the ratio of
polyunsaturated to saturated fatty acid intake (Table 3).
Conversely, intake of total carbohydrates, starch, sugars
fibers and alcohol were all inversely associated with diet-
ary selenium intake.
The age, education, and menopausal status adjusted
odds ratio for incident type 2 diabetes comparing the
highest to the lowest quintile of selenium intake was
2.64 (95% CI: 1.73, 4.01), with evidence of a progressive
increase in risk across quintiles (P-trend < 0.001)
(Table 4). The odds ratio estimates were not consider-
ably altered after additional adjustment for BMI, smok-
ing status, dietary variables and body weight change
during follow-up (OR 2.39, 95% CI: 1.32, 4.32).
When selenium was used as a continuous variable, the
odds ratios associated with a 10 μg/d increase in sele-
nium intake were 1.29 (95% CI: 1.17, 1.41) in the
reduced model, and 1.29 (95% CI: 1.10, 1.52) in the fully
adjusted model. The linearity of the relationship
between selenium intake and risk of diabetes was con-
firmed in spline regression models (not shown). There
was no statistical evidence that BMI, menopausal status,
smoking and alcohol intake modified the association of
selenium intake with diabetes risk (data not shown).
Discussion
In this prospective study, dietary selenium intake
showed a strong and graded association with the risk of
type 2 diabetes in a large sample of Italian women. The
association was independent of a number of potential
confounding factors including socio-demographic,
anthropometric, lifestyle and dietary variables. To our
knowledge, this is one of the few epidemiological studies
to examine the prospective relationship of dietary sele-
nium intake with incident type 2 diabetes in Europe.
Recent findings from observational studies and rando-
mised clinical trials from the US, a selenium-replete
population, indicate that high selenium status or
selenium supplementation may be associated with an
increased risk of type 2 diabetes [5-8]. Data from the
Third National Health and Nutrition Examination Sur-
vey (NHANES III) [5] and from NHANES 2003-2004
[ 8 ]s h o w e ds i g n i f i c a n tc r o ss-sectional associations
between high serum selenium levels and the prevalence
of type 2 diabetes in representative samples of the US
population. Furthermore, selenium supplementation
(200 μg/d) in the Nutritional Prevention of Cancer
(NPC) trial, conducted in the Eastern US, was associated
with an increased risk of incident type 2 diabetes com-
pared to placebo (hazard ratio, 1.55, 95% CI: 1.03, 2.33).
T h ei n c r e a s ei nr i s kw a sl a r g ely limited to participants
with high baseline selenium levels (hazard ratio of 2.70
in the highest tertile of serum selenium) [6]. Finally, the
Selenium and Vitamin E Cancer Prevention Trial
(SELECT), conducted among 35,000 North American
men aged 50 and older, was prematurely stopped
b e c a u s eo fl a c ko fe f f i c a c yo fv i t a m i nEa n ds e l e n i u m
supplementation (200 μg/d) in cancer prevention and
because of a small, though not statistically significant
increase in the number of cases of adult onset diabetes
in participants taking only selenium (relative risk com-
pared to placebo 1.07, 99% CI: 0.94, 1.22) [7]. In
disagreement with these studies, cross-sectional findings
from the Health Professionals Follow-up Study showed
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or without cardiovascular disease) than among healthy
control participants [24]. In addition, a longitudinal ana-
lysis of US young adults participating in the CARDIA
Study showed a lower risk of type 2 diabetes in the
highest quintile of toenail selenium compared to the
lowest (hazard ratio 0.59, 95% CI: 0.36, 0.97), although
the point estimates in the intermediate quintiles were
null [25].
With regard to European populations, there is little
epidemiological evidence. In the Supplementation with
Antioxidant Vitamins and Minerals (SU.VI.MAX) trial,
an antioxidant supplement containing 100 μg of sele-
nium, 120 mg of vitamin C, 30 mg of vitamin E, 6 mg
of b-carotene, and 20 mg of zinc had no effect on
plasma glucose levels after 7.5 years of follow-up, but in
this study there was a significant positive association
between plasma selenium and glucose levels at both
baseline and follow-up [17]. Conversely, a recent report
from the EVA (Epidemiology of Vascular Ageing) study
in France showed that higher plasma selenium concen-
trations (1.19-1.97 μmol/L) were associated with a mar-
ginally significant decreased risk of dysglycemia
(impaired fasting glucose or diabetes) in men over a
9-year follow-up [18]. No association was found in
women. It should be noted that in an earlier analysis of
the same study, plasma selenium concentrations were
positively, though non-significantly, associated with
baseline glucose levels in women and with prevalent
diabetes in men [26].
Mechanistic evidence that may explain an association
between high selenium exposure and increased risk of
type 2 diabetes is limited; therefore any such discussion
is highly speculative at the present time. Selenium has a
narrow therapeutic range and large inter-individual
variability in terms of metabolic sensitivity [27,28]. Sele-
n i u ms p e c i e ss u c ha ss e l e n ite and selenate may impair
Table 1 Baseline characteristics* of participants according to diabetes status at the follow-up examination in the
ORDET Study (N = 7,182)
Diabetic cases Non-diabetics P
N 253 6,929
Selected characteristics
Age 51.2 47.1 < 0.001
BMI (kg/m
2) 29.5 (0.25) 24.8 (0.05) < 0.001
Current smoker (%) 17.8 19.8 0.43
Education (%) > 8 years 36.0 54.3 < 0.001
Post-menopausal status (%) 50.0 32.9 < 0.001
Total proteins (g/day) 79.8 (1.42) 75.8 (0.27) 0.006
Animal proteins (g/day) 54.5 (1.19) 51.2 (0.23) 0.006
Animal fat 37.6 (0.95) 38.0 (0.18) 0.74
Ratio saturated/polyunsaturated fatty acids 0.32 (0.008) 0.31 (0.001) 0.18
Total carbohydrates (g/day) 215.1 (4.00) 215.4(0.76) 0.96
Starch (g/day) 146.5 (3.13) 145.5(0.60) 0.75
Sugars (g/day) 68.6 (1.67) 69.9(0.32) 0.47
Fibers (g/day) 20.3 (0.07) 19.7 (0.38) 0.12
Alcohol (g/day) 8.2 (0.81) 10.0(0.16) 0.03
Energy (kcal/day) 1789 (30.18) 1788 (5.74) 0.97
Selenium intake (μg/day) 60.9 (1.11) 56.8 (0.212) < 0.001
* Age-adjusted means (standard error), except where indicated.
Table 2 Food sources of selenium in the ORDET Study
Food items %
Red meat 21.7
Fish 14.5
White meat 7.0
Processed meat 7.0
Cheese 5.7
Pasta 5.4
Bread 5.2
Eggs 5.1
Fruit 3.8
Tomatoes 3.8
Milk 3.7
Cake 3.6
Offal 2.7
Snacks 1.8
Wine 1.8
Rice 1.0
Yoghurt 0.9
Potatoes 0.8
Leafy vegetable raw 0.8
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response in muscle with glycogen depletion and
increased rates of glycolysis [29]. Moreover, high-
selenium diets may stimulate the release of glucagon,
promoting hyperglycemia [30], or may induce over-
expression of glutathione peroxidase-1 (GPx-1) and
other antioxidant selenoproteins resulting in insulin
resistance and obesity [31-33]. Likewise in humans, a
strongly positive correlation between GPx activity and
insulin resistance was found in a group of non-diabetic
pregnant women [34]. From a mechanistic point of
view, selenium intakes above the level recommended for
optimal activity of antioxidant selenoproteins such as
glutathione peroxidases (55 μg/day, resulting in serum
or plasma concentrations of 70-90 μg/L) [16,35], will
result in the non-specific incorporation of selenomethio-
nine replacing methionine in albumin and other
proteins [1]. The metabolic pathways involving this
extra pool of selenium are not fully understood, and
m a yb er e s p o n s i b l ef o rs o m eo ft h ea d v e r s ee f f e c t so f
high selenium exposure on glucose metabolism.
The present study may suffer from the inherent lim-
itations associated with the use of self-reported semi-
quantitative food-frequency questionnaires, an approach
prone to misclassification of the exposure of interest.
Indeed, the correlation between dietary selenium intake
and selenium biomarkers has been inconsistent across
studies, ranging from positive, strong associations
Table 3 Baseline characteristics* of participants according to energy-adjusted quintiles† of dietary selenium intake in
the ORDET Study (N = 7,182)
Quintiles of dietary selenium intake (μg/day)
I II III IV V P trend
N 1,437 1,436 1,437 1,436 1,436
Average Se intake (μg/d) 41.7 50.2 55.7 62.0 75.1 -
Age 47.3 47.1 47.6 47.3 46.9 0.37
BMI (kg/m
2) 24.2 24.5 24.8 25.3 25.9 < 0.001
Current smoker (%) 19.1 18.5 18.3 21.9 21.0 0.03
Education (%) > 8 years 56.5 53.6 51.5 53.7 52.9 0.09
Post-menopausal status (%) 34.0 35.7 32.8 34.6 31.1 0.08
Total proteins (g/day) 67.1 69.2 72.6 78.9 91.9 < 0.001
Animal proteins (g/day) 39.9 44.7 48.7 55.1 68.1 < 0.001
Animal fat 36.3 36.4 36.5 38.5 42.1 < 0.001
Ratio saturated/polyunsaturated fatty acids 0.28 0.31 0.31 0.32 0.34 < 0.001
Total carbohydrates (g/day) 240.5 216.4 209.0 207.3 203.6 < 0.001
Starch (g/day) 164.0 147.5 141.3 139.6 135.2 < 0.001
Sugars (g/day) 76.5 68.8 67.7 67.7 68.4 < 0.001
Fibers (g/day) 21.2 19.1 18.9 19.1 19.5 < 0.001
Alcohol (g/day) 10.3 10.3 10.4 9.9 8.8 0.001
Energy (kcal/day) 1843 1741 1728 1768 1840 0.59
* Age-adjusted means, except where indicated
† Quintiles of dietary Se intake were adjusted for total energy intake using the residual method [20]
Table 4 Odds Ratios (95% Confidence Intervals) of incident type 2 diabetes by quintiles* of dietary selenium intake in
the ORDET Study
Quintiles of dietary selenium intake (μg/day)
I II III IV V P trend†
N° cases of diabetes 32 42 45 55 79
Range Se intake (μg/day) ≤ 47.0 47.1-53.0 53.1-58.5 58.6-65.9 > 65.9
Model 1 (reduced) 1.00 1.31
(0.82-2.09)
1.38
(0.87-2.19)
1.74
(1.12-2.72)
2.64
(1.73-4.01)
< 0.001
Model 2 (fully-adjusted) 1.00 1.42
(0.87-2.34)
1.43
(0.86-2.38)
1.65
(0.98-2.78)
2.39
(1.32-4.32)
0.005
* Quintiles of dietary selenium intake were adjusted for total energy intake using the residual method [20]
Model 1: Adjusted for age, education, menopausal status
Model 2: Adjusted for age, education, menopausal status, BMI, smoking (never, past, current), alcohol intake (abstainers, ≤ 12 g/day, > 12 g/day), energy intake
(not from alcohol), saturated/polyunsaturated fatty acids ratio, animal proteins, total carbohydrates, and weight change between the baseline and follow-up
examinations
† Test for linear trend performed on median intake for each quintile
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itation of our study is the lack of validation data for
food-frequency estimates of selenium intake in our
population, which makes it impossible for us to correct
selenium and other nutritional covariates for random or
systematic measurement error. However, while the use
of questionnaire data to estimate selenium intake has
raised concerns in settings with high variability in the
selenium content of foods and high frequency of use of
vitamin and mineral supplements, several factors point
to the validity of the selenium intake estimates in the
present study. First, the ORDET study compiled a
detailed database of the selenium content of local foods,
with ad hoc measurements of the selenium content of a
variety of foods. Second, previous studies have shown
little variability of selenium in food contents as well as
of selenium status throughout Italy [40], making it easier
to estimate selenium intake through questionnaire data.
Indeed, the range of dietary selenium intake in the
present study is compatible with previous estimates of
selenium status, based on biomarkers, from Italian
populations [40-42]. Finally, despite the lack of data on
the use of dietary supplements containing selenium in
the ORDET study, a nationwide survey conducted in
Italy in the 90s [43] showed a small percentage of sup-
plement users among women (less than 5%). Thus, it is
likely that very few participants were using supplements
during the 80s when the ORDET sample was recruited.
In our setting, assessing selenium exposure through eva-
luation of dietary intake may even have advantages over
selenium biomarkers, which may be influenced by the
intake of other nutrients such as methionine [41], by
smoking and other life-style variables [44], drug use
[44], and the chemical species of selenium itself [35].
As a further potential limitation of the present study,
we cannot rule out confounding effects by unmeasured
(e.g. family history of diabetes, physical activity) or
unknown factors that may have contributed to our find-
ings. The association between selenium intake and dia-
betes could be driven by a common dietary factor or by
general over-nutrition. For example, red meat, the main
source of selenium in our study, has been positively
associated with type 2 diabetes in prospective settings
among women [45], and contains compounds such as
preservatives, additives, and nitrates that might con-
found the observed associations of selenium intake with
diabetes risk.
Our study may have underestimated the incidence of
type 2 diabetes, as case identification was based on self-
report and record linkage to hospital and prescription
databases. It should be noted, however, that case ascer-
tainment of incident diabetes in the follow up of the
ORDET study complied with the protocol of the Inter-
Act Study, an EU-funded large scale collaboration
involving 350,000 subjects with over 10,000 incident dia-
betic cases http://www.inter-act.eu/. In addition, given
the voluntary nature of the study population, we cannot
rule out the potential for a “healthy volunteer’ bias,
which may have contributed to a low incidence of type
2 diabetes in this study.
Finally, given the prospective design, differential mis-
classification seems unlikely and non-differential mis-
classification would result in an underestimation of the
association between selenium intake and diabetes risk
[46]. Major strengths of the present study are its pro-
spective nature, which limits the possibility of reverse
causality, high standardization of data collection, length
and high rate of follow-up.
Conclusions
The use of selenium enriched foods, fertilizers, and sup-
plements has increased markedly in many Western
countries in recent years [47,48] because of the percep-
tion that selenium can potentially reduce the risk of
cancer and other chronic diseases. Hence, from a public
health perspective it is essential to ensure that selenium
fortification of the food supply and use of selenium sup-
plements do not exacerbate the current diabetes
epidemic.
The present study adds to the evidence of an associa-
tion between high selenium exposure and potential dia-
betes risk. Future studies are needed to investigate the
link between selenium exposure and metabolic effects in
more detail across different ranges of exposure, as well
as potential underlying mechanisms [14,49].
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